The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Subscribe To Our Newsletter & Stay Updated
